Historical Evolution of the Polymorphous Adenocarcinoma

Hernández-Prera, Juan C.

doi:10.1007/s12105-018-0964-9

Cited by 16 publications

(13 citation statements)

References 52 publications

(94 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the limitations of this study is related to the unresolved issue of the existence of CAMSG as separate entity or variant of PCA. [2][3][4][5] Although morphologically both neoplasms are very similar, they show differences regarding tumor location, metastatic tendency and molecular abnormalities. CAMSGs have predilection for the tongue and a greater tendency for lymph node metastases.…”

Section: Discussionmentioning

confidence: 99%

“…Since its description in 1983 polymorphous low-grade adenocarcinoma has been the subject of some controversy, mainly regarding terminology and related entities. [1][2][3][4] The most recent WHO classification has changed its name to polymorphous adenocarcinoma (PAC). 4 The debate about the existence of a variant that may represent an independent entity (cribriform adenocarcinoma of minor salivary glands) is still an open one.…”

Section: Introductionmentioning

confidence: 99%

“…4 The debate about the existence of a variant that may represent an independent entity (cribriform adenocarcinoma of minor salivary glands) is still an open one. [2][3][4][5] It is a tumor that mostly affects minor salivary glands, especially the palate. The estimated annual incidence rate is 0.051 cases per 100 000 persons and it represents 41% of all carcinomas of the minor salivary gland.…”

Section: Introductionmentioning

confidence: 99%

“…18 In contrast to PAC, most cribriform adenocarcinomas of minor salivary glands (CAMSGs) show rearrangements rather than mutations in PRKD genes (PRKD1-3), including ARID1A-PRKD1 and DDX3X-PRKD1 gene fusions. [2][3][4][5] E710D mutation can be detected in cytological samples 19 but for that to be the case, the entity must first be suspected. In this study we describe our experience with 11 cases of PAC.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Fine needle aspiration cytology of polymorphous adenocarcinoma of the salivary glands: A report of 11 patients and review of the literature

Jiménez‐Heffernan

Rodríguez-García

González‐Peramato

et al. 2020

Diagnostic Cytopathology

View full text Add to dashboard Cite

Background: Polymorphous adenocarcinoma (PAC) is a rare malignant tumor of the minor salivary glands. It has an infiltrative growth, variable architectural patterns, neurotropism and cellular monomorphism. Approximately 75% of the cases show a specific mutation in the protein kinase D1 (PRKD1) gene. Reflecting the rarity of the tumor and intraoral location, the cytologic experience is limited with few reported series. In this study we analyze our cytologic experience to determine if a preoperative diagnosis is possible. Methods: A retrospective study of 11 patients with PAC in which a cytologic study was available. A review of the literature was also performed. Results: Our study shows that PAC has relatively constant cytological features. The analysis of the cytological literature although it shows some heterogeneity, also reveals repetitive cytological findings. Smears are cellular with irregular groups some showing pseudopapillary branching morphology. Monolayered clusters and small acinar structures are also present. Most cases have small metachromatic globules embedded within the groups determining a cylindromatous pattern. Tumoral cells are small and uniform with scarce to moderate cytoplasm. Nuclei are round and oval with occasional grooves and small nucleoli. Conclusion: PAC has characteristic cytological features that together with its location in minor salivary gland must make us consider it preoperatively. It may resemble basal cell adenoma and epithelial-rich pleomorphic adenoma so we should be cautious in the final diagnosis. Whenever possible, the characteristic cytomorphology of PCA should make us evaluate the mutational status of PRKD1 gene since it may permit a more accurate diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Fine needle aspiration cytology of polymorphous adenocarcinoma of the salivary glands: A report of 11 patients and review of the literature

Jiménez‐Heffernan

Rodríguez-García

González‐Peramato

et al. 2020

Diagnostic Cytopathology

View full text Add to dashboard Cite

show abstract

“…In the current case, polymorphous low-grade adenocarcinoma (PLGA) was ruled out based on histopathological features including a well-defined broad front invasive pattern seen in this case as opposed to an infiltrative cord-like one typical in PLGA [16]. The presence of microcystic areas with abundant vacuolated colloid-like PAS-positive secretory material within the microcystic spaces, low-grade vesicular nuclei with a distinctive centrally located small nucleolus, the lack of perineural invasion, and the diffuse pattern of staining seen with S100 protein and mammaglobin were further features which support the diagnosis of MASC.…”

Section: Discussionmentioning

confidence: 99%

Mammary Analogue Secretory Carcinoma of the Palate: Case Report and Review of the Literature

Boliere

Murphy

Qaisi

et al. 2019

Case Reports in Dentistry

View full text Add to dashboard Cite

Mammary analogue secretory carcinoma (MASC) is a recently described salivary gland tumor, with a limited number of published reports. Less than three hundred cases have been reported in the literature and only 18 of these cases have been reported in minor palatal salivary glands, though publication bias is likely a factor. We present a case of a 57-year-old male who was diagnosed with MASC tumor presenting in a minor salivary gland and briefly review the current literature. MASC has a variety of histological features and different range of clinical behaviors. The histopathological diagnosis of MASC can be difficult, and the immunohistochemical profile of MASC is still being updated. The gold standard for MASC diagnosis is cytogenetics, with the majority having a translocation t(12;15)(p133;q25). Presently, there is no conclusive evidence that MASC should be treated differently than any other low-grade malignant salivary gland tumors, though high-grade transformation has been described.

show abstract

New Systemic Therapies in Salivary Gland Cancer

Vathiotis

Johnson

Argiris

2023

Critical Issues in Head and Neck Oncology

View full text Add to dashboard Cite

Salivary gland cancer (SGC) encompasses a group of rare malignancies with distinct molecular, histologic, and clinical characteristics. Rarity as well as evolving disease heterogeneity have made treatments particularly challenging, with classic chemotherapy agents showing at best moderate antitumor efficacy in patients with recurrent or metastatic SGC. Recent advances in genomic profiling have provided relevant targets for different subtypes of SGC, enabling tailoring of therapeutic approaches. Despite the lack of predictive biomarkers, treatment with immune checkpoint inhibitors also appears to benefit a subgroup of patients. This chapter aims to give a comprehensive overview of novel approaches to systemic therapy for patients with recurrent or metastatic SGC.

show abstract

Historical Evolution of the Polymorphous Adenocarcinoma

Cited by 16 publications

References 52 publications

Fine needle aspiration cytology of polymorphous adenocarcinoma of the salivary glands: A report of 11 patients and review of the literature

Fine needle aspiration cytology of polymorphous adenocarcinoma of the salivary glands: A report of 11 patients and review of the literature

Mammary Analogue Secretory Carcinoma of the Palate: Case Report and Review of the Literature

New Systemic Therapies in Salivary Gland Cancer

Contact Info

Product

Resources

About